Improvement of skeletal muscle insulin sensitivity by 1 week of SGLT2 inhibitor use.
SGLT2 inhibitor
diabetes mellitus
glucose fluctuation
insulin resistance
skeletal muscle
Journal
Endocrine connections
ISSN: 2049-3614
Titre abrégé: Endocr Connect
Pays: England
ID NLM: 101598413
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
14
05
2020
accepted:
04
06
2020
pubmed:
25
6
2020
medline:
25
6
2020
entrez:
25
6
2020
Statut:
ppublish
Résumé
It is currently unclear whether sodium-glucose co-transporter 2 (SGLT2) inhibitor administration can improve the insulin sensitivity as well as rapidly reduce plasma glucose concentrations in humans during the early phase of treatment initiation. This study aimed to investigate the effect of SGLT2 inhibitor on insulin sensitivity in the early phase of treatment initiation. This single-center, open label, and single-arm prospective study recruited 20 patients (14 men) with type 2 diabetes mellitus (T2DM). We examined the patients' metabolic parameters before and 1 week after SGLT2 inhibitor (10 mg/day of empagliflozin) administration. The glucose infusion rate (GIR) was evaluated using the euglycemic hyperinsulinemic glucose clamp technique. Changes in laboratory and anthropometric parameters before and after SGLT2 inhibitor administration were analyzed according to the change in the GIR. The BMI, body fat amount, skeletal muscle amount, systolic blood pressure, and triglyceride level significantly decreased along with the treatment, while urinary glucose level and log GIR value significantly increased. Notably, changes in the GIR after SGLT2 inhibitor administration, which indicated improvement in peripheral insulin sensitivity, were negatively correlated with T2DM duration and positively with reduction in fluctuation of daily plasma glucose profiles before and after treatment. SGLT2 inhibitor improved insulin sensitivity in the skeletal muscle independent of anthropometric changes. Patients with short duration of T2DM and insulin resistance can be good candidates for short-term SGLT2 inhibitor administration to improve insulin sensitivity in the skeletal muscle.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
It is currently unclear whether sodium-glucose co-transporter 2 (SGLT2) inhibitor administration can improve the insulin sensitivity as well as rapidly reduce plasma glucose concentrations in humans during the early phase of treatment initiation. This study aimed to investigate the effect of SGLT2 inhibitor on insulin sensitivity in the early phase of treatment initiation.
METHODS AND RESULTS
RESULTS
This single-center, open label, and single-arm prospective study recruited 20 patients (14 men) with type 2 diabetes mellitus (T2DM). We examined the patients' metabolic parameters before and 1 week after SGLT2 inhibitor (10 mg/day of empagliflozin) administration. The glucose infusion rate (GIR) was evaluated using the euglycemic hyperinsulinemic glucose clamp technique. Changes in laboratory and anthropometric parameters before and after SGLT2 inhibitor administration were analyzed according to the change in the GIR. The BMI, body fat amount, skeletal muscle amount, systolic blood pressure, and triglyceride level significantly decreased along with the treatment, while urinary glucose level and log GIR value significantly increased. Notably, changes in the GIR after SGLT2 inhibitor administration, which indicated improvement in peripheral insulin sensitivity, were negatively correlated with T2DM duration and positively with reduction in fluctuation of daily plasma glucose profiles before and after treatment.
CONCLUSION
CONCLUSIONS
SGLT2 inhibitor improved insulin sensitivity in the skeletal muscle independent of anthropometric changes. Patients with short duration of T2DM and insulin resistance can be good candidates for short-term SGLT2 inhibitor administration to improve insulin sensitivity in the skeletal muscle.
Identifiants
pubmed: 32580152
doi: 10.1530/EC-20-0082
pii: EC-20-0082.R2
pmc: PMC7354734
doi:
pii:
Types de publication
Journal Article
Langues
eng
Pagination
599-606Références
Diabetes Care. 2008 Oct;31(10):1927-32
pubmed: 18556343
Mol Cell Biochem. 2018 Dec;449(1-2):251-255
pubmed: 29679277
J Clin Endocrinol Metab. 2012 Mar;97(3):1020-31
pubmed: 22238392
Diabet Med. 2013 Jul;30(7):803-17
pubmed: 23413806
Diabetes Care. 2014 Aug;37(8):2108-13
pubmed: 24824546
Endocrinology. 2016 Mar;157(3):1029-42
pubmed: 26713783
J Diabetes Sci Technol. 2013 Jan 01;7(1):100-10
pubmed: 23439165
J Clin Invest. 2014 Feb;124(2):509-14
pubmed: 24463448
Diabetologia. 2010 Jul;53(7):1270-87
pubmed: 20361178
J Atheroscler Thromb. 2018 Jan 1;25(1):27-39
pubmed: 28966336
Diabetes Metab Res Rev. 2000 Mar-Apr;16(2):125-32
pubmed: 10751752
Biochim Biophys Acta. 2010 Mar;1801(3):266-71
pubmed: 19782153
Diabetes Obes Metab. 2011 Jun;13(6):511-6
pubmed: 21272188
Diabetologia. 2017 Feb;60(2):215-225
pubmed: 27878313
Diabetes. 1999 May;48(5):1113-9
pubmed: 10331418
N Engl J Med. 2017 Aug 17;377(7):644-657
pubmed: 28605608
Diabetes. 2017 May;66(5):1172-1184
pubmed: 28246292
N Engl J Med. 2008 Jun 12;358(24):2545-59
pubmed: 18539917
J Clin Endocrinol Metab. 2004 Mar;89(3):1481-4
pubmed: 15001651
N Engl J Med. 2015 Nov 26;373(22):2117-28
pubmed: 26378978
Am J Physiol. 1979 Sep;237(3):E214-23
pubmed: 382871
Diabetes Obes Metab. 2018 May;20(5):1311-1315
pubmed: 29316197
N Engl J Med. 2004 Feb 12;350(7):664-71
pubmed: 14960743
Eur J Endocrinol. 2018 Apr;178(4):R113-R125
pubmed: 29371333
J Diabetes Complications. 2017 May;31(5):912-917
pubmed: 28242267
Diabetes Care. 2019 May;42(5):931-937
pubmed: 30885955
Diabet Med. 2018 Aug;35(8):1096-1104
pubmed: 29655290
Diabetes Obes Metab. 2019 Dec;21(12):2684-2693
pubmed: 31423699
Circ J. 2002 Nov;66(11):987-92
pubmed: 12419927
Diabetes. 1995 Nov;44(11):1249-58
pubmed: 7589820
Diabetologia. 2010 Sep;53(9):1976-85
pubmed: 20526759
PLoS Biol. 2018 Jul 24;16(7):e2005143
pubmed: 30040822